WO2025069896A1 - 生体留置物 - Google Patents
生体留置物 Download PDFInfo
- Publication number
- WO2025069896A1 WO2025069896A1 PCT/JP2024/030858 JP2024030858W WO2025069896A1 WO 2025069896 A1 WO2025069896 A1 WO 2025069896A1 JP 2024030858 W JP2024030858 W JP 2024030858W WO 2025069896 A1 WO2025069896 A1 WO 2025069896A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biodegradable polymer
- drug
- stent
- lactic acid
- porous structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/89—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0069—Three-dimensional shapes cylindrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
- A61F2250/0024—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity made from both porous and non-porous parts, e.g. adjacent parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Definitions
- the present invention relates to a living body indwelling.
- Stents are medical devices that are used to treat various diseases caused by narrowing or blocking of biological lumens such as blood vessels. They are delivered to the affected area in a biological lumen by a stent delivery system and then placed in place to expand the affected area, such as a narrowed or blocked area, and secure the lumen.
- a typical stent has linear struts that form the outer periphery of a cylinder with gaps formed in it. After being delivered to the affected area, the stent applies tensile strength (expansion force) to the affected area when it is expanded (expanded) within the biological lumen. By maintaining its tensile strength for a specified period of time, the stent keeps the affected area expanded and secures the lumen of the biological lumen.
- Patent Document 1 discloses a mesh-covered stent in which a mesh is arranged to cover the outer periphery of a stent in order to prevent peripheral embolism when the stent is placed.
- the mesh has an expandable knit structure and expands in response to the expansion of the stent, thereby preventing the scattering of plaque or thrombus when the stent is expanded.
- Mesh-covered stents may use a polymer mesh to improve the mesh's ability to follow the stent when it expands, to improve delivery to the affected area, and to reduce the impact that may be caused to the biological lumen after treatment.
- a polymer mesh may be used to improve the mesh's ability to follow the stent when it expands, to improve delivery to the affected area, and to reduce the impact that may be caused to the biological lumen after treatment.
- polymer materials are more likely to cause inflammation in tissues than metal materials. For this reason, in known drug-eluting stents, when a polymer is used as a drug carrier, a biodegradable or bioinert polymer is often selected. However, it is believed that inflammation caused by the polymer can be suppressed by the drug released (eluted) from the stent. Therefore, when using a biodegradable polymer as a constituent material for the stent, it is believed that the effects of inflammation caused by the polymer can be reduced by using a polymer that disappears quickly after drug release is complete.
- the inventors of the present invention based on the above findings, have discovered that in a mesh-covered stent (biological implant) equipped with a polymer mesh (porous structure), by adjusting the time from placement of the mesh-covered stent until the polymer mesh decomposes and disappears, and the time from placement of the mesh-covered stent until drug release is complete, it is possible to effectively suppress the onset of inflammation caused by the polymer mesh while preventing the scattering of plaque and thrombus when the stent is expanded.
- the present invention aims to provide a living body implant that can effectively suppress the onset of inflammation caused by a porous structure made of a biodegradable polymer while preventing the scattering of plaque and thrombus during stent expansion.
- the present invention comprises an expandable cylindrical stent and a porous structure made of a first biodegradable polymer arranged so as to cover the stent, the stent has a drug carrying portion including a second biodegradable polymer and a drug; A living body indwelling device, wherein the decomposition time of the porous structure is substantially the same as or shorter than the decomposition time of the drug-carrying part.
- the stent is constructed from a non-biodegradable material;
- the stent is constructed from a non-biodegradable material;
- first biodegradable polymer and the second biodegradable polymer are the same polymer, and the first biodegradable polymer and the second biodegradable polymer are selected from the group consisting of a homopolymer of one type of monomer selected from the group consisting of lactic acid, caprolactone, glycolic acid, dioxanone, butyrolactone, valerolactone, hydroxybutyric acid, and trimethylene carbonate, or a copolymer of two or more types of monomers.
- the first biodegradable polymer and the second biodegradable polymer are different polymers
- the first biodegradable polymer is at least one selected from the group consisting of polyglycolic acid, polycaprolactone, glycolic acid-lactic acid copolymer, ⁇ -caprolactone-lactic acid copolymer, and glycolic acid- ⁇ -caprolactone copolymer
- the second biodegradable polymer is at least one selected from the group consisting of polylactic acid, lactic acid- ⁇ -caprolactone copolymer, lactic acid-glycolic acid copolymer, and polydioxanone.
- the first biodegradable polymer is at least one selected from the group consisting of polyglycolic acid or polyglycolic acid-polylactic acid copolymer
- the second biodegradable polymer is at least one selected from the group consisting of polylactic acid, lactic acid- ⁇ -caprolactone copolymer, and polydioxanone.
- the porous structure decomposes and disappears after a certain period of time has passed since placement, and drug release from the drug-carrying portion disposed in the stent continues until the porous structure decomposes and disappears. Therefore, the above-mentioned indwelling device can effectively suppress the onset of inflammation caused by the porous structure made of a biodegradable polymer while preventing the scattering of plaque and thrombus when the stent is expanded.
- FIG. 1 is a schematic plan view showing a stent delivery system including a living body indwelling device according to an embodiment.
- FIG. 2 is a schematic plan view showing a reduced diameter state of the living body indwelling device according to the embodiment.
- FIG. 2 is a schematic plan view showing an expanded state (diameter-expanded state) of the living body indwelling device according to the embodiment.
- FIG. 4 is a partially enlarged view showing a part of the living body indwelling device in the state shown in FIG. 3 .
- FIG. 2 is an enlarged cross-sectional view showing a cross section of a part of a stent and a porous structure, illustrating an example of the arrangement of a drug carrying portion.
- FIG. 1 is a schematic plan view showing a stent delivery system including a living body indwelling device according to an embodiment.
- FIG. 2 is a schematic plan view showing a reduced diameter state of the living body indwelling device according to the embodiment.
- FIG. 2 is an enlarged cross-sectional view showing a cross section of a part of a stent and a porous structure, illustrating an example of the arrangement of a drug carrying portion.
- FIG. 2 is an enlarged cross-sectional view showing a cross section of a part of a stent and a porous structure, illustrating an example of the arrangement of a drug carrying portion.
- the living body indwelling device 100 will be described below with reference to Figures 1 to 7.
- FIG. 1 is a schematic plan view showing a stent delivery system 300 including a living body retainer 100 according to an embodiment of the present invention.
- FIG. 2 is a schematic plan view showing a contracted state of the living body retainer 100 according to an embodiment.
- FIG. 3 is a schematic plan view showing an expanded state of the living body retainer 100 according to an embodiment.
- FIG. 4 is a partially enlarged view showing the living body retainer 100 according to an embodiment.
- FIGS. 5 to 7 are enlarged cross-sectional views showing schematic examples of the arrangement of the drug carrying portion 18 in the stent 10.
- the direction in which the living body indwelling device 100 extends is referred to as the "axial direction.”
- the above-mentioned axial direction is the direction from the tip 10A to the base end 10B shown in FIG. 2.
- the side that is inserted into the living body is referred to as the "tip side,” and the side opposite the tip side where the surgeon operates the medical device is referred to as the "base side.”
- the direction perpendicular to the above-mentioned "axial direction” is referred to as the "radial direction" of the living body indwelling device 100.
- the stent delivery system 300 includes a bioinsertable device 100 and a balloon catheter 200.
- the balloon catheter 200 is delivered in a deflated state to the affected area and is used to expand and place the indwelling device 100 near the affected area.
- the balloon catheter 200 has a long catheter body 210, a balloon 220 provided at the tip of the catheter body 210, and a hub 230 fixed to the base end of the catheter body 210.
- the outer tube has an expansion lumen formed therein through which an expansion fluid flows to expand the balloon 220.
- the tip of the outer tube is fixed to the base end of the balloon 220.
- the base end of the outer tube is fixed to the hub 230.
- a guidewire lumen into which a guidewire is inserted is formed inside the inner tube.
- the tip of the inner tube penetrates the inside of the balloon 220 and opens further distal than the balloon 220.
- the base end of the inner tube penetrates the side wall of the outer tube further proximal than the balloon 220 and is fixed to the outer tube.
- the balloon 220 is a member that, for example, expands inside the narrowed portion (lesion portion) to push open the narrowed portion.
- the tip side of the balloon 220 is fixed to the outer wall surface of the inner tube.
- the base end side of the balloon 220 is fixed to the outer wall surface of the tip of the outer tube. Therefore, the inside of the balloon 220 communicates with the expansion lumen formed in the outer tube.
- the balloon 220 is capable of receiving an expansion fluid from the base end opening 231 via the expansion lumen. The balloon 220 expands when the expansion fluid flows in, and contracts and becomes folded when the expansion fluid is discharged.
- the balloon 220 is preferably made of a flexible material that expands and contracts with the inflow and outflow of the expansion fluid, examples of which include polymeric materials such as polyolefin, cross-linked polyolefin, polyester, polyester elastomer, polyvinyl chloride, polyurethane, polyurethane elastomer, polyphenylene sulfide, polyamide, polyamide elastomer, fluororesin, silicone rubber, and latex rubber.
- the balloon 220 is not limited to the above polymeric materials used alone, and may be made of a film in which the above polymeric materials are appropriately laminated.
- the expansion fluid may be a gas or liquid, examples of which include gases such as helium gas, CO2 gas, and O2 gas, and liquids such as saline and X-ray contrast medium.
- the hub 230 has a proximal opening 231 that communicates with the expansion lumen of the outer tube.
- the proximal opening 231 functions as a port for the inflow and outflow of the expansion fluid.
- the material of which the hub 230 is made is not particularly limited, but examples include thermoplastic resins such as polyethylene, polyurethane, polyester, polypropylene, polycarbonate, polyamide, polysulfone, polyarylate, and methacrylate-butylene-styrene copolymer.
- thermoplastic resins such as polyethylene, polyurethane, polyester, polypropylene, polycarbonate, polyamide, polysulfone, polyarylate, and methacrylate-butylene-styrene copolymer.
- the indwelling device 100 is used, for example, to treat a narrowed or blocked area occurring in a blood vessel, a bile duct, a trachea, an esophagus, a urethra, or other living lumen.
- the indwelling device 100 is a so-called balloon expansion type, which is mounted on a balloon 220 in a crimped state, and is expanded after being delivered to the lesion and placed in the lesion.
- the indwelling device 100 can also be configured as a so-called self-expanding stent.
- the indwelling device 100 generally comprises an expandable cylindrical stent 10 and a porous structure 20 made of a first biodegradable polymer arranged to cover the stent 10.
- the stent 10 also has a drug-carrying portion 18 that contains a second biodegradable polymer and a drug.
- the stent 10 has a generally cylindrical shape with an inner lumen extending in the axial direction.
- a tip end 10A is located at the distal end of the stent 10, and a base end 10B is located at the proximal end of the stent 10.
- the stent 10 is formed so that it can expand (as shown in Figure 3) and contract (as shown in Figure 2) in the radial direction.
- the stent 10 has linear rings 11 that form the outer periphery of a cylindrical shape with gaps formed therein, and link portions 12 that connect the rings 11 together through the gaps.
- the wavy ring 11 has a plurality of first strut sections 15 formed with straight or curved lines, a second strut section 16 formed with straight or curved lines, and a curved section 17 formed between the first strut section 15 and the second strut section 16.
- the ring 11 also has a plurality of third strut sections 14 formed with straight or curved lines that are adjacent to one side of the axial direction (for example, the left side in Figure 4) of the link section 12 and that are arranged in pairs in the circumferential direction (up and down in Figure 4).
- the rings 11 are arranged in a row along the axial direction, and adjacent rings 11 in the axial direction are integrated by link portions 12. Therefore, by increasing or decreasing the number of rings 11, it is possible to easily obtain a stent 10 of the desired length.
- the porous structure 20 which has a large number of through-holes, is arranged to cover the outer periphery of the stent 10 (the portion of the surface 19 of the ring 11 facing outward), as shown in Figures 3, 4, and 5.
- the porous structure 20 is configured to be expandable in response to the expansion of the stent 10, as shown in Figures 2 and 3.
- the porous structure 20 extends along the axial direction of the stent 10 and has a mesh structure.
- the gaps in the mesh structure of the porous structure 20 can be configured to be smaller than the gaps between adjacent rings 11.
- the porous structure 20 includes, for example, any of knitted fabrics (knits), woven fabrics (braids), and molded products.
- the porous structure 20 can be configured, for example, by stockinette stitch.
- stockinette stitch By configuring the porous structure 20 by stockinette stitch, it is possible to prevent the axial length of the porous structure 20 from shortening as the stent 10 expands. Since stockinette stitch itself is a known knitting method, a detailed description of it is omitted in this specification.
- the porous structure 20 is woven, the woven fabric is configured by a known weaving method.
- the porous structure 20 is a molded product, the porous structure 20 is configured by a cylindrical sheet having regularly arranged voids. The size, shape, and number of the stitches and weaves of the porous structure 20 are not particularly limited as long as they can prevent peripheral embolism when the stent 10 is expanded.
- the thread diameter of the porous structure 20 is not particularly limited, but can be, for example, 20 ⁇ m.
- the porous structure 20 is not limited to being made of knitted fabric.
- the porous structure 20 can also be made of, for example, knitted fabric, woven fabric (braid), etc.
- the size, shape, and number of stitches of the porous structure 20 are not particularly limited as long as they can prevent peripheral embolism caused by plaque or thrombus when the stent 10 expands.
- the porous structure 20 can be fixed at any location, such as the tip 10A, base end 10B, and link portion 12 of the stent 10. There are no particular limitations on the method of fixing the porous structure 20 to the stent 10, but any method can be used, such as adhesive fixation using polymers or paraffin, or fixation using mechanical means such as cable ties, clips, and thread.
- the drug-carrying portion 18 can be disposed only in at least a portion 19a (hereinafter, referred to as "opposing portion 19a") facing the porous structure 20 in a cross-sectional view perpendicular to the axial direction of the surface 19 of the ring 11 forming the stent 10.
- the drug-carrying portion 18 may be in any form as long as it is present on at least a portion of the surface 19 of the ring 11 forming the stent 10 or at least a portion of the stent 10 itself.
- the drug-carrying portion 18 may be present in at least a portion or all of the first strut portion 15, the second strut portion 16, and the third strut portion 14 of the ring 11, and may or may not be present in the link portion 12 and/or the curved portion 17.
- the drug-carrying portion 18 is present in the first strut portion 15, the second strut portion 16, and the third strut portion 14, and is not present in the link portion 12 and the curved portion 17. This reduces the phenomenon of the drug-carrying portion 18 peeling off during expansion.
- the drug-carrying portion 18 is formed only on the opposing portion 19a of the ring 11. According to the first embodiment, the drug-carrying portion 18 is selectively arranged on the opposing portion 19a, so that the drug contained in the drug-carrying portion 18 is selectively released only from the side on which the porous structure 20 is arranged (the opposing portion 19a side). Therefore, according to the first embodiment, the inflammatory reaction induced by the porous structure 20 can be more effectively suppressed and prevented with a smaller amount of drug than when the drug-carrying portion 18 is arranged to cover the entire area of the surface 19 of the ring 11. In other words, the risk of inflammation caused by contact between the porous structure 20 and living tissue near the opposing portion 19a can be effectively reduced and eliminated.
- the shape and size (cross-sectional shape, range provided on opposing portion 19a, etc.) of drug-carrying portion 18 are not particularly limited, and can be set appropriately depending on the cross-sectional shape and size of ring 11.
- the cross-sectional shape of ring 11 is square, approximately square, rectangular, or approximately rectangular, drug-carrying portion 18 can be formed over the entire range of the surface of ring 11 that can come into contact with porous structure 20.
- the thickness of drug-carrying portion 18 is not particularly limited, and can be appropriately selected depending on the desired decomposition time, drug content, etc.
- the thickness of drug-carrying portion 18 can be, for example, 1 to 20 ⁇ m.
- the stent 10 is made of a non-biodegradable material, and the drug-carrying portion 18 can be arranged to cover the entire area in a cross-sectional view perpendicular to the axial direction of the surface 19 of the ring 11 that forms the stent 10.
- the drug-carrying portion 18 is arranged in areas other than the contact area with the porous structure 20. Therefore, according to the second embodiment, the drug concentration can be maintained more sufficiently than when the drug-carrying portion 18 is arranged only on the opposing portion 19a side of the ring 11, so that the inflammatory reaction induced by the porous structure 20 can be sufficiently suppressed and prevented.
- the indwelling device 100 can be arranged, for example, with an anti-inflammatory agent on the side where the porous structure 20 contacts the biological tissue, and another drug that can be used to treat the target can be arranged on the other covered parts. Therefore, according to the second embodiment, the inflammatory reaction induced by the porous structure 20 can be more effectively suppressed and prevented, and other necessary treatments can be performed at the same time.
- the thickness of the drug-carrying portion 18 is not particularly limited and is appropriately selected depending on the decomposition time, drug content, etc.
- the thickness of the drug-carrying portion 18 may be, for example, 0.5 to 10 ⁇ m.
- the entire stent 10 (the entire ring 11 forming the stent 10) is composed of the drug-carrying portion 18.
- the stent 10 itself can function as the drug-carrying portion 18.
- the manufacturing process can be reduced, which is preferable from the viewpoint of mass production.
- a large amount of anti-inflammatory agent can be placed on the contact area side (opposing portion 19a side) of the stent 10 that contacts the porous structure 20, and another drug that can be used to treat the target can be placed on the other parts. Therefore, according to the third embodiment, it is possible to more effectively suppress and prevent inflammatory reactions induced by the porous structure 20, and to perform other required treatments at the same time.
- the first and second embodiments are preferred, with the first embodiment being more preferred, from the standpoint of further suppressing and preventing inflammatory reactions, higher tensile strength of the stent 10, and a longer period during which the tensile strength is maintained.
- examples of the non-biodegradable material that can be used for the stent 10 include carbon fiber, metal materials, and polymer materials.
- the non-biodegradable material is a metal material or a polymer material. From the viewpoint of further reducing inflammation, it is particularly preferable that the non-biodegradable material is a metal material.
- the metal material used when the stent 10 is made of a metal material is not particularly limited, and metal materials that are normally used in the stent product field can be used.
- stainless steels such as SUS304, SUS316, SUS316L, SUS420J2, and SUS630, tantalum, titanium, nickel-titanium alloys, tantalum-titanium alloys, nickel-aluminum alloys, Inconel, gold, platinum, iridium, tungsten, and cobalt-chromium (Co-Cr) alloys and other cobalt-based alloys can be mentioned.
- SUS316L which has the best corrosion resistance, is preferred.
- cobalt-based alloys MP35N, L605, etc. are preferred.
- the polymer material used when the stent 10 is made of a polymer material is not particularly limited, and any polymer material normally used in the product field of the stent 10 can be used.
- Specific examples include polyolefins such as polyethylene and polypropylene, aromatic polyesters such as polyethylene terephthalate, cellulose-based polymers such as cellulose acetate and cellulose nitrate, and fluorine-containing polymers such as polytetrafluoroethylene and tetrafluoroethylene-ethylene copolymers.
- the stent 10 can be suitably formed from a material selected from the above-mentioned materials according to the application site, etc.
- a material selected from the above-mentioned materials according to the application site, etc.
- the metal material has excellent strength, so the indwelling device 100 can be placed more securely at the lesion.
- the stent 10 is formed from a polymer material, the polymer material has excellent flexibility, so the indwelling device 100 has excellent reach (deliverability) to the lesion.
- the stent 10 is a self-expanding type, a superelastic alloy such as a nickel-titanium alloy is preferable since it needs the ability to return to its original shape.
- a superelastic alloy such as a nickel-titanium alloy
- stainless steel is preferable since it is less likely to return to its original shape after expansion.
- the stent 10 is made of carbon fiber, it will have excellent effects in that it is high in strength, has excellent flexibility, and is highly safe in the living body.
- the material, shape, size, etc. of the stent 10 there are no particular limitations on the material, shape, size, etc. of the stent 10, so long as it can be placed in a lesion that has developed in a lumen in a living body, such as a blood vessel, bile duct, trachea, esophagus, or urethra.
- the outer diameter of the stent 10 before expansion is typically, for example, 1.0 to 3.0 mm.
- the wall thickness of the stent 10 is, for example, 0.05 to 0.25 mm.
- the length (axial length) of the stent 10 is, for example, 5 to 50 mm.
- the manufacturing method of the stent 10 is not particularly limited, and may be appropriately selected from commonly used manufacturing methods depending on the structure and material of the stent 10. For example, a manufacturing method using an etching technique such as laser etching or chemical etching, or a laser cutting technique may be selected.
- etching technique such as laser etching or chemical etching, or a laser cutting technique
- the decomposition time of the porous structure 20 is substantially the same as or shorter than the decomposition time of the drug-carrying portion 18.
- the porous structure 20 is made of a biodegradable polymer, and the decomposition time of the porous structure 20 is equal to or shorter than the decomposition time of the drug-carrying portion 18.
- the decomposition time of the porous structure 20 and the drug carrier portion 18 is, for example, 2 to 6 months, preferably 3 to 5 months, and more preferably 3 to 4 months.
- the porous structure 20 can suppress the scattering of plaque and thrombus when the indwelling device 100 is placed, while an endothelial cell layer can be sufficiently formed on the stent 10.
- one month is considered to be 30 days.
- the first biodegradable polymer and the second biodegradable polymer are the same polymer, and the first biodegradable polymer and the second biodegradable polymer are selected from the group consisting of a homopolymer of one monomer selected from the group consisting of lactic acid, caprolactone, glycolic acid, and dioxanone, or a copolymer of two or more monomers.
- the weight average molecular weight of the biodegradable polymer used in the indwelling device 100 is not particularly limited and is appropriately selected according to the desired decomposition time (biodegradation rate). Specifically, the weight average molecular weight of the biodegradable polymer is preferably 10,000 or more, more preferably 50,000 to 1,000,000, and even more preferably 100,000 to 500,000. The number average molecular weight of the biodegradable polymer is preferably 5,000 or more, more preferably 20,000 to 800,000, and even more preferably 30,000 to 200,000.
- weight average molecular weight (weight average molecular weight, number average molecular weight)
- Methods for measuring molecular weight include gel permeation chromatography (GPC), light scattering, viscosity measurement, and mass spectrometry (TOFMASS, etc.).
- the weight average molecular weight is a value measured by GPC using polystyrene as a standard substance.
- the decomposition time of the porous structure 20 is shorter than the decomposition time of the drug-carrying portion 18 (such a configuration is referred to as the "fifth embodiment").
- the porous structure 20 decomposes and disappears, leaving only the stent 10, and then the drug-carrying portion 18 decomposes and disappears. Therefore, while the porous structure 20 exists, the drug continues to be released from the drug-carrying portion 18 to the biological tissue with which the porous structure 20 is in contact. Therefore, with this configuration, it is possible to simultaneously suppress and prevent peripheral embolism and reduce and eliminate the risk of inflammation of the biological tissue due to contact with the porous structure 20.
- the inflammatory reaction induced by the porous structure 20 can be more effectively suppressed and prevented, and other necessary treatments can be performed simultaneously and for a long period of time.
- the difference between the decomposition time of the porous structure 20 and the decomposition time of the drug-carrying portion 18 is 2 hours or more, preferably 3 hours or more, and more preferably 1 month or more.
- the upper limit of the difference between the decomposition time of the porous structure 20 and the decomposition time of the drug carrying portion 18 is not particularly limited, but is, for example, 22 months or less, preferably 12 months or less, and more preferably 5 months or less. By providing such a time difference, it is possible to achieve a better balance between suppressing and preventing peripheral embolism and reducing and eliminating the risk of inflammation of tissues due to contact with the porous structure 20.
- the decomposition time of the porous structure 20 is preferably within 5 months, more preferably within 4 months, even more preferably between 2 and 4 months, and particularly preferably between 3 and 4 months.
- the decomposition time of the drug-carrying portion 18 is preferably more than 5 months, more preferably more than 6 months, even more preferably between 7 and 12 months, and particularly preferably between 8 and 12 months. With such a decomposition time, the porous structure 20 can suppress the scattering of plaque and thrombus when the biological indwelling device 100 is placed, while an endothelial cell layer can be sufficiently formed on the stent 10.
- the first biodegradable polymer constituting the porous structure 20 and the second biodegradable polymer constituting the drug carrying portion 18 may be a combination of materials such that the decomposition time of the porous structure 20 is shorter than the decomposition time of the drug carrying portion 18.
- the first biodegradable polymer and the second biodegradable polymer may be the same as the biodegradable polymers exemplified above.
- the first biodegradable polymer is at least one selected from the group consisting of polyglycolic acid, polycaprolactone, glycolic acid-lactic acid copolymer, caprolactone-lactic acid copolymer, and glycolic acid-caprolactone copolymer.
- biodegradable polymers with many structural units derived from lactic acid such as polylactic acid, lactic acid-glycolic acid copolymers containing lactic acid at 90 mol % or more of the total monomers, and lactic acid- ⁇ -caprolactone copolymers containing lactic acid at 96 mol % or more of the total monomers, or polydioxanone, are preferably used for the drug carrying portion 18.
- the second biodegradable polymer is preferably at least one selected from the group consisting of polylactic acid, lactic acid- ⁇ -caprolactone copolymers, lactic acid-glycolic acid copolymers, and polydioxanone.
- the first biodegradable polymer and the second biodegradable polymer are different polymers
- the first biodegradable polymer is at least one selected from the group consisting of polyglycolic acid, polycaprolactone, glycolic acid-lactic acid copolymer, caprolactone-lactic acid copolymer, and glycolic acid-caprolactone copolymer
- the second biodegradable polymer is preferably at least one selected from the group consisting of polylactic acid, lactic acid- ⁇ -caprolactone copolymer, lactic acid-glycolic acid copolymer, and polydioxanone.
- the first biodegradable polymer and the second biodegradable polymer are different polymers
- the first biodegradable polymer is at least one selected from the group consisting of polyglycolic acid and glycolic acid-lactic acid copolymer
- the second biodegradable polymer is at least one selected from the group consisting of polylactic acid, lactic acid- ⁇ -caprolactone copolymer, and polydioxanone.
- the method of controlling the decomposition time of the porous structure 20 includes a method of controlling the composition (e.g., glass transition temperature), molecular weight (e.g., the length of the thread constituting the porous structure 20), and crystallinity (e.g., the spinning conditions of the porous structure 20, the presence or absence of annealing) of the first biodegradable polymer (e.g., the decomposition time is shorter when the crystallinity is low, for example, the crystallinity of the porous structure 20 is controlled to be 0% or more and 40% or less), a method of appropriately selecting the presence or absence of terminal treatment (e.g., the decomposition time is longer when terminal treatment is performed by esterification), and a method of using an additive.
- the composition e.g., glass transition temperature
- molecular weight e.g., the length of the thread constituting the porous structure 20
- crystallinity e.g., the spinning conditions of the porous structure 20, the presence or absence of anne
- the method of controlling the molecular weight, composition (glass transition temperature), or crystallinity of the first biodegradable polymer is preferably used from the viewpoint of ease of control of the decomposition time.
- the method of controlling the decomposition time of the drug carrying part 18 includes a method of controlling the molecular weight, composition, or crystallinity of the second biodegradable polymer (for example, the larger the crystallinity, the longer the decomposition time, for example, controlling the crystallinity of the second biodegradable polymer to more than 40%), a method of appropriately selecting the presence or absence of end treatment (for example, when end treatment is performed by esterification, the decomposition time is longer), a method of controlling the compounding ratio of the drug, and the mixing ratio and mixing method of the second biodegradable polymer and the drug, a method of using an additive, a method of controlling the shape of the drug, etc.
- a method of controlling the molecular weight, composition, or crystallinity of the second biodegradable polymer, a method of controlling the compounding ratio of the drug, and the mixing ratio and mixing method of the second biodegradable polymer and the drug are preferably used.
- the biodegradation rate slows down when the molecular weight (weight average molecular weight) of the biodegradable polymer increases.
- a method can be used in which the molecular weight (weight average molecular weight) of the first biodegradable polymer used in the porous structure 20 is adjusted to be smaller than the molecular weight (weight average molecular weight) of the second biodegradable polymer used in the drug carrying section 18.
- the molecular weight (weight average molecular weight) of the first biodegradable polymer is, for example, 250,000 or less, more preferably 100,000 or more and 200,000 or less, more preferably 120,000 or more and 180,000 or less, more preferably 140,000 or more and 180,000 or less.
- the molecular weight (weight average molecular weight) of the second biodegradable polymer is, for example, 50,000 or more, more preferably 100,000 or more and 500,000 or less, more preferably 100,000 or more and 250,000 or less, particularly preferably 100,000 or more and 120,000 or less.
- the molecular weight (number average molecular weight) of the first biodegradable polymer is, for example, 150,000 or less, more preferably 30,000 or more and 100,000 or less.
- the molecular weight (number average molecular weight) of the second biodegradable polymer is, for example, 30,000 or more, and more preferably 40,000 or more and 150,000 or less.
- the crystallinity of the first biodegradable polymer is, for example, 0% or more and 40% or less, more preferably 0% or 20% or more and 40% or less, and even more preferably 20% or more and 40% or less.
- the crystallinity of the second biodegradable polymer is, for example, 0% or more and 50% or less, preferably 0% or more than 40% and 45% or less, and more preferably 0%.
- the porous structure 20 may contain a biodegradable polymer that has been irradiated with an electron beam in advance.
- a biodegradable polymer that has been irradiated with an electron beam in advance.
- the bonds within the (co)polymer are more likely to be broken, and the rate of biodegradation increases. Therefore, even when biodegradable polymers of the same composition are used, the decomposition time can be adjusted by irradiating the biodegradable polymer used in the porous structure 20 with an electron beam in advance.
- the combinations of the first biodegradable polymer and the second biodegradable polymer include polyglycolic acid A and poly-L-lactic acid F; glycolic acid-L-lactic acid copolymer B and poly-L-lactic acid F; glycolic acid-caprolactone copolymer C and poly-L-lactic acid F; caprolactone-DL-lactic acid copolymer D and poly-L-lactic acid F; glycolic acid-DL-lactic acid copolymer E and poly-L-lactic acid F; polyglycolic acid A and polydioxanone G; glycolic acid-L-lactic acid copolymer B and polydioxanone G; glycolic acid- Caprolactone copolymer C and polydioxanone G; caprolactone-DL lactic acid copolymer D and polydioxanone G; glycolic acid-DL lactic acid copolymer E and polydioxanone G; polyglycolic acid A and polyDL lactic acid H; glycoliclic
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and poly-L-lactic acid F; glycolic acid-L-lactic acid copolymer B and poly-L-lactic acid F; glycolic acid-caprolactone copolymer C and poly-L-lactic acid F; caprolactone-DL-lactic acid copolymer D and poly-L-lactic acid F; polyglycolic acid A and polydioxanone G; glycolic acid-L-lactic acid copolymer B and polydioxanone G; glycolic acid-caprolactone copolymer C and polydioxanone G; caprolactone-DL-lactic acid copolymer D and polydioxanone G; polyglycolic acid A and poly-DL-lactic acid H; glycolic acid-L-lactic acid copolymer B and poly-DL-lactic acid H; glycolic acid- ⁇ -caprolactone copolymer C and
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and poly-L-lactic acid F; glycolic acid-L-lactic acid copolymer B and poly-L-lactic acid F; glycolic acid-caprolactone copolymer C and poly-L-lactic acid F; caprolactone-DL-lactic acid copolymer D and poly-L-lactic acid F.
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and poly-L-lactic acid F; glycolic acid-L-lactic acid copolymer B and poly-L-lactic acid F.
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and polydioxanone G; glycolic acid-L lactic acid copolymer B and polydioxanone G; glycolic acid-caprolactone copolymer C and polydioxanone G; caprolactone-DL lactic acid copolymer D and polydioxanone G.
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and polydioxanone G; glycolic acid-L lactic acid copolymer B and polydioxanone G.
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and poly DL-lactic acid H; glycolic acid-L-lactic acid copolymer B and poly DL-lactic acid H; glycolic acid- ⁇ -caprolactone copolymer C and poly DL-lactic acid H; ⁇ -caprolactone-DL-lactic acid copolymer D and poly DL-lactic acid H.
- the combination of the first biodegradable polymer and the second biodegradable polymer is selected from polyglycolic acid A and poly DL-lactic acid H; glycolic acid-L-lactic acid copolymer B and poly DL-lactic acid H.
- the combination of the first biodegradable polymer and the second biodegradable polymer may be selected from glycolic acid-L-lactic acid copolymer B and poly-L-lactic acid F; glycolic acid-caprolactone copolymer C and poly-L-lactic acid F; caprolactone-DL-lactic acid copolymer D and poly-L-lactic acid F; glycolic acid-L-lactic acid copolymer B and polydioxanone G; glycolic acid-caprolactone copolymer C and polydioxanone G; caprolactone-DL-lactic acid copolymer D and polydioxanone G; glycolic acid-L-lactic acid copolymer B and poly-DL-lactic acid H; glycolic acid- ⁇ -caprolactone copolymer C and poly-DL-lactic acid H; ⁇ -caprolactone-DL-lactic acid copolymer D and poly-DL-lactic acid H.
- the indwelling device 100 in this combination can be particularly suitable
- the combination of the first biodegradable polymer and the second biodegradable polymer is polydioxanone G and poly-L-lactic acid F.
- the indwelling device 100 with this combination is particularly suitable for use in carotid artery stenosis.
- the size of the porous structure 20 is not particularly limited, and is set within a range that does not significantly impair the performance of the stent body, such as the ability to reach the lesion (deliverability) and irritation to the blood vessel wall.
- the porous structure 20 is arranged so as to cover the entire outer circumferential surface of the stent 10.
- the thickness of the porous structure 20 is not particularly limited, and is set within a range that does not significantly impair the performance of the stent 10, such as the ability to deliver to the lesion (deliverability) and irritation to the blood vessel wall.
- the thickness of the porous structure 20 (the radial thickness on the cross-sectional view perpendicular to the axial direction shown in Figures 5 to 7) is not particularly limited, and is set within a range that does not significantly impair the performance of the stent 10, such as the ability to reach the lesion (deliverability) and irritation to the blood vessel wall.
- the thickness of the porous structure 20 is preferably 1 ⁇ m to 100 ⁇ m, and more preferably 5 ⁇ m to 50 ⁇ m.
- the above thickness can more effectively suppress and prevent peripheral embolism associated with the scattering of plaque and thrombus during or after placement of the stent 10.
- the function related to the thickness of the porous structure 20 is preferably thin within a range in which mechanical strength is maintained.
- a thinner porous structure 20 is advantageous in terms of preventing the foldability and device profile from becoming larger, and improving the passage through the lesion. In other words, if the porous structure 20 is formed too thick, it is disadvantageous in terms of foldability and device profile, and the stent inner diameter (expansion diameter) becomes smaller after placement in the lesion, reducing the effect of improving blood flow.
- the radial thickness of the stent 10 (the radial thickness on the cross-sectional view in the cross-sectional view perpendicular to the axial direction shown in Figures 5 to 7) can be configured to be larger than the thickness of the porous structure 20.
- the thickness of the stent 10 can be configured to be, for example, 60 ⁇ m to 120 ⁇ m.
- the method for producing the porous structure 20 and the method for coating the stent 10 with the porous structure 20 can be similar to or appropriately modified from the methods described in International Publication No. WO 2008/062414.
- the drug-carrying portion 18 contains a drug in addition to the second biodegradable polymer.
- the drug contained in the drug-carrying portion 18 is not particularly limited and can be appropriately selected depending on the desired application. Considering the induction of inflammation by the porous structure 20, it is preferable that the drug contains an anti-inflammatory agent or an immunosuppressant.
- the anti-inflammatory agent is not particularly limited and a known anti-inflammatory agent can be used.
- the anti-inflammatory agent is a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, or a combination thereof.
- anti-inflammatory agents include alclofenac, alclometasone dipropionate, algestone acetonide, alpha amylase, amcinafal, amcinafide, amfenac sodium, amiprilose hydrochloride, anakinra, nostic, anitrazafen, apazone, balsalazide disodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelain, broperamol, budesonide, carprofen, cycloprofen, synthazone, cliprofen, clobetasol propionate, clobetasone butyrate, clopirac, cloticasone propionate, cormetasone acetate, cortodoxone, deflazacort, desonide, desoximetasone, dexamethasone, dexamethasone dipropionate, diclofenac potassium, diclofenac sodium, d
- the immunosuppressant is also not particularly limited, and known immunosuppressants can be used. Examples include sirolimus, everolimus, biolimus A9, pimecrolimus, zotarolimus, sirolimus derivatives such as ABT-578, biolimus (e.g., Biolimus A9 (registered trademark)), tacrolimus, azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, gusperimus, and the like.
- biolimus e.g., Biolimus A9 (registered trademark)
- tacrolimus e.g., azathioprine
- cyclosporine cyclosporine
- cyclophosphamide cyclophosphamide
- mycophenolate mofetil gusperimus, and the like.
- the above immunosuppressants may be used alone or in combination of two or more types.
- the above immunosuppressants may also
- the amount of drug contained in the drug-carrying portion 18 is not particularly limited as long as it is an amount that provides the desired medicinal effect, but it is preferable to contain a large amount of drug from the viewpoint of further exerting an anti-inflammatory effect.
- the amount of drug contained in the drug-carrying portion 18 is preferably 30% by mass or more and 60% by mass or less, and more preferably 45% by mass or more and 50% by mass or less, relative to the total amount (100% by mass) of the second biodegradable polymer and the drug. With this composition, an appropriate amount of drug can be effectively released over a specified period of time.
- the drug-carrying portion 18 may contain other drugs in addition to the anti-inflammatory agent.
- the drug-carrying portion 18 further contains other drugs
- the other drugs are not particularly limited, but are preferably drugs that suppress stenosis and blockage of the vascular system that may occur when the stent is placed in the lesion.
- anticancer drugs such as paclitaxel, docetaxel, vinblastine, vindesine, irinotecan, and pirarubicin
- immunosuppressants such as sirolimus, everolimus, pimecrolimus, and sirolimus derivatives such as ABT-578, tacrolimus, azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, and gusperimus
- antibiotics such as mitomycin, adriamycin, doxorubicin, actinomycin, daunorubicin, idarubicin, pirarubicin, aclarubicin, epirubicin, and zinostatin stimalamer
- antithrombotic drugs such as aspirin and ticlopidine
- the indwelling device 100 comprises an expandable cylindrical stent 10 and a porous structure 20 made of a first biodegradable polymer arranged to cover the stent 10, the stent 10 having a drug-carrying portion 18 containing a second biodegradable polymer and a drug, and the decomposition time of the porous structure 20 is substantially the same as or shorter than the decomposition time of the drug-carrying portion 18.
- the porous structure 20 decomposes and disappears after a certain period of time has passed since placement, and the release of the drug from the stent 10 continues until the porous structure 20 decomposes and disappears. Therefore, the bioinstrument 100 can effectively suppress the onset of inflammation caused by the porous structure 20 made of a biodegradable polymer while preventing the scattering of plaque and thrombus when the stent 10 is expanded.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP24871697.9A EP4755408A1 (en) | 2023-09-29 | 2024-08-29 | Living body indwelling object |
| JP2025548642A JPWO2025069896A1 (cg-RX-API-DMAC7.html) | 2023-09-29 | 2024-08-29 | |
| US19/629,236 US20260215943A1 (en) | 2023-09-29 | 2026-03-26 | Living body indwelling object |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023-169879 | 2023-09-29 | ||
| JP2023169879 | 2023-09-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US19/629,236 Continuation US20260215943A1 (en) | 2023-09-29 | 2026-03-26 | Living body indwelling object |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2025069896A1 true WO2025069896A1 (ja) | 2025-04-03 |
Family
ID=95203066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2024/030858 Ceased WO2025069896A1 (ja) | 2023-09-29 | 2024-08-29 | 生体留置物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20260215943A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4755408A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2025069896A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2025069896A1 (cg-RX-API-DMAC7.html) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004509205A (ja) | 2000-09-15 | 2004-03-25 | イーストマン ケミカル カンパニー | 生分解性ポリマー及び生分解性ポリマー組成物の分解速度の減速方法並びにそれらの組成物 |
| WO2006126182A2 (en) | 2005-05-24 | 2006-11-30 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
| JP2007097706A (ja) * | 2005-09-30 | 2007-04-19 | Terumo Corp | ステント |
| WO2007083797A1 (ja) * | 2006-01-23 | 2007-07-26 | Terumo Kabushiki Kaisha | ステント |
| WO2008001952A1 (en) | 2006-06-30 | 2008-01-03 | Kyoto University | Thin film multilocular structure comprising collagen, material for tissue regeneration containing the same and method for producing the same |
| JP2008514719A (ja) | 2004-10-01 | 2008-05-08 | ラムズコア, インコーポレイテッド | 便利に移植可能な徐放性薬物処方物 |
| WO2008062414A2 (en) | 2006-11-22 | 2008-05-29 | Inspiremd Ltd. | Optimized stent jacket |
| WO2009041691A1 (ja) * | 2007-09-28 | 2009-04-02 | Terumo Kabushiki Kaisha | 生体内留置物 |
| JP2011528275A (ja) | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ,インク. | 薬物送達医療デバイス |
| JP2012196252A (ja) * | 2011-03-18 | 2012-10-18 | Terumo Corp | 薬剤溶出ステント |
| JP2014504170A (ja) * | 2010-11-12 | 2014-02-20 | タイレックス・インコーポレイテッド | 有効医薬品成分を含む固着装置 |
| WO2016114216A1 (ja) * | 2015-01-13 | 2016-07-21 | テルモ株式会社 | 生分解性ステント |
| JP2023169879A (ja) | 2022-05-17 | 2023-11-30 | ダイオーズ インコーポレイテッド | Led色及び輝度制御装置及び方法 |
-
2024
- 2024-08-29 JP JP2025548642A patent/JPWO2025069896A1/ja active Pending
- 2024-08-29 EP EP24871697.9A patent/EP4755408A1/en active Pending
- 2024-08-29 WO PCT/JP2024/030858 patent/WO2025069896A1/ja not_active Ceased
-
2026
- 2026-03-26 US US19/629,236 patent/US20260215943A1/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004509205A (ja) | 2000-09-15 | 2004-03-25 | イーストマン ケミカル カンパニー | 生分解性ポリマー及び生分解性ポリマー組成物の分解速度の減速方法並びにそれらの組成物 |
| JP2008514719A (ja) | 2004-10-01 | 2008-05-08 | ラムズコア, インコーポレイテッド | 便利に移植可能な徐放性薬物処方物 |
| WO2006126182A2 (en) | 2005-05-24 | 2006-11-30 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
| JP2007097706A (ja) * | 2005-09-30 | 2007-04-19 | Terumo Corp | ステント |
| WO2007083797A1 (ja) * | 2006-01-23 | 2007-07-26 | Terumo Kabushiki Kaisha | ステント |
| WO2008001952A1 (en) | 2006-06-30 | 2008-01-03 | Kyoto University | Thin film multilocular structure comprising collagen, material for tissue regeneration containing the same and method for producing the same |
| WO2008062414A2 (en) | 2006-11-22 | 2008-05-29 | Inspiremd Ltd. | Optimized stent jacket |
| WO2009041691A1 (ja) * | 2007-09-28 | 2009-04-02 | Terumo Kabushiki Kaisha | 生体内留置物 |
| JP2011528275A (ja) | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ,インク. | 薬物送達医療デバイス |
| JP2014504170A (ja) * | 2010-11-12 | 2014-02-20 | タイレックス・インコーポレイテッド | 有効医薬品成分を含む固着装置 |
| JP2012196252A (ja) * | 2011-03-18 | 2012-10-18 | Terumo Corp | 薬剤溶出ステント |
| WO2016114216A1 (ja) * | 2015-01-13 | 2016-07-21 | テルモ株式会社 | 生分解性ステント |
| JP2023169879A (ja) | 2022-05-17 | 2023-11-30 | ダイオーズ インコーポレイテッド | Led色及び輝度制御装置及び方法 |
Non-Patent Citations (1)
| Title |
|---|
| FARHATNIA YASMIN, TAN AARON, MOTIWALA AAMIR, COUSINS BRIAN G., SEIFALIAN ALEXANDER M.: "Evolution of covered stents in the contemporary era: clinical application, materials and manufacturing strategies using nanotechnology", BIOTECHNOLOGY ADVANCES., ELSEVIER PUBLISHING, BARKING., GB, vol. 31, no. 5, 1 September 2013 (2013-09-01), GB , pages 524 - 542, XP093299164, ISSN: 0734-9750, DOI: 10.1016/j.biotechadv.2012.12.010 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260215943A1 (en) | 2026-07-30 |
| EP4755408A1 (en) | 2026-06-10 |
| JPWO2025069896A1 (cg-RX-API-DMAC7.html) | 2025-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9345816B2 (en) | Methods of treatment with drug delivery after biodegradation of the stent scaffolding | |
| US9446172B2 (en) | Modification of bioabsorbable stent to reduce thrombogenecity | |
| US10076591B2 (en) | Absorbable coating for implantable device | |
| AU2017378839B2 (en) | Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers | |
| US9408952B2 (en) | Pediatric application of bioabsorbable polymer stents in infants and children with congenital heart defects | |
| WO2010141173A1 (en) | Terpolymers containing lactide and glycolide | |
| WO2009129503A2 (en) | Block copolymer comprising at least one polyester block and a poly(ethylene glycol) block | |
| JP5684863B2 (ja) | 生体内留置物 | |
| US9839537B2 (en) | Bioresorbable polymer scaffold treatment of coronary and peripheral artery disease in diabetic patients | |
| WO2009142934A2 (en) | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer | |
| WO2015119976A1 (en) | Modified pla polymer and method of making and using | |
| EP2214598A2 (en) | Random amorphous terpolymer containing lactide and glycolide | |
| CN105025945B (zh) | 用于外周动脉疾病的药物递送装置 | |
| JPWO2007116646A1 (ja) | 生体内留置物 | |
| WO2025204184A1 (ja) | 生体留置物 | |
| JP2025059657A (ja) | 生体留置物 | |
| WO2026070929A1 (ja) | 生体内留置物及び多孔構造体の製造方法 | |
| JP2026060303A (ja) | 生体留置物 | |
| JP2026061390A (ja) | 生体留置物、及び多孔構造体の製造方法 | |
| HK1197738A (en) | An absorbable coating for implantable device | |
| HK1180983A (en) | An absorbable coating for implantable device | |
| HK1180983B (en) | An absorbable coating for implantable device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24871697 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2025548642 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024871697 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202617037776 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |